RPG Life Sciences Ltd

RPG Life Sciences Limited informed the National Stock Exchange of India Limited and BSE Limited that Samir Rane, Vice President, Sales & Marketing - Main Division, has ceased to be a Senior Management Personnel with effect from the close of business hours on July 31, 2026, due to retirement upon attaining the age of superannuation.

RPG Life Sciences Limited announced it has unanimously approved the sale of its Active Pharmaceutical Ingredients (API) business to its wholly-owned subsidiary, RPG Active Pharma Limited (RPGAP), for approximately Rs 33.55 crore, subject to adjustments. The transaction is expected to be completed on or before September 30, 2026. Additionally, India Life Sciences Fund IV Domestic and Vistaject Fund will invest a total of Rs 243.33 crore for a roughly 40% stake in RPGAP, with a commitment to potentially invest up to Rs 700 crore for growth opportunities, and RPGAP will acquire the entire stake of Actis Generics Private Limited for Rs 80 crore.

Net profit of RPG Life Sciences rose 17.00% to Rs 30.76 crore in the quarter ended June 2026 as against Rs 26.29 crore during the previous quarter ended June 2025. Sales rose 15.85% to Rs 195.69 crore in the quarter ended June 2026 as against Rs 168.92 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales195.69168.92 16 OPM %22.1221.00 - PBDT47.3640.57 17 PBT41.4635.43 17 NP30.7626.29 17 Powered by Capital Market - Live

RPG Life Sciences will hold a meeting of the Board of Directors of the Company on 28 July 2026.

RPG Life Sciences (RPG LS) has partnered with Archerchem Healthcare to launch Naproxen and Esomeprazole combination for the first time in India by strengthening the existing business relationship with Archerchem. Naprosyn ES is a combination of Naproxen and Esomeprazole, designed to deliver effective anti-inflammatory solution along with gastro protection. The combination has been co-developed by Archerchem Healthcare along with its development partner. RPG LS will exclusively market and distribute Naprosyn ES across the country and Archerchem as the exclusive supplier. The product addresses a significant unmet need in patients requiring long-term Nonsteroidal Anti-Inflammatory Drug (NSAID) therapy, particularly those at risk of gastrointestinal complications. The differentiated formulation is expected to improve patient compliance and enable safer long-term pain management, especially among elderly and gastro-sensitive populations.  

RPG Life Sciences announced that the Annual General Meeting(AGM) of the company will be held on 23 July 2026.

The profit appears lower due to the exceptional gain that was recorded in Q4 FY25. Total operating expenses for Q4 FY26 added up to Rs 144.06 crore, up 22.5% YoY. Profit before tax in Q4 FY26 stood at Rs 40.20 crore, down by 70.2% from Rs 134.90 crore in Q4 FY25. For FY26, the company posted net profit and revenue of Rs 115.17 crore (down 37.1% YoY) and Rs 707.52 crore (up 8.3% YoY), respectively. The company said that in Q4, the Domestic Formulations (DF) business again delivered market-beating growth of 18.2%, compared to the Indian Pharma Market (IPM), which grew by 10.1% in the same period; a 1.8 times growth placing us significantly ahead of the market. The API division demonstrated strong comeback and registered a growth of 144.3% in Q4 on the back of unit coming back to operations. The growth surge especially stands out considering the fire in our API manufacturing plant in January 2025 and the timely restoration of our facility. Ashok Nair, managing director, RPG Life Sciences, said: 'Overall, we have built solid momentum with healthy growth in Q4 and for the full fiscal year, driven by sharper field effectiveness, operational discipline and an unwavering focus on our key brands. Looking ahead, we intend to strengthen our new product pipeline, sharpen equity of our existing brands, and drive field force effectiveness.' The board of directors at its meeting held today has recommended a final dividend of Rs 24 per equity share for FY25-26. RPG Life Sciences is an integrated research-based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The scrip jumped 10.85% to currently trade at Rs 2242 on the BSE. Powered by Capital Market - Live

RPG Life Sciences announced that the Board of Directors of the Company at its meeting held on 29 April 2026, inter alia, have recommended the final dividend of Rs 24 per equity Share (i.e. 300%) , subject to the approval of the shareholders.

Net profit of RPG Life Sciences declined 74.52% to Rs 29.90 crore in the quarter ended March 2026 as against Rs 117.35 crore during the previous quarter ended March 2025. Sales rose 23.62% to Rs 176.89 crore in the quarter ended March 2026 as against Rs 143.09 crore during the previous quarter ended March 2025. For the full year,net profit declined 37.15% to Rs 115.17 crore in the year ended March 2026 as against Rs 183.24 crore during the previous year ended March 2025. Sales rose 8.28% to Rs 707.52 crore in the year ended March 2026 as against Rs 653.43 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales176.89143.09 24 707.52653.43 8 OPM %18.5617.81 -20.7924.43 - PBDT44.8430.37 48 171.78171.71 0 PBT39.1025.00 56 150.30150.28 0 NP29.90117.35 -75 115.17183.24 -37 Powered by Capital Market - Live

Net profit of RPG Life Sciences declined 36.64% to Rs 22.13 crore in the quarter ended December 2025 as against Rs 34.93 crore during the previous quarter ended December 2024. Sales rose 4.24% to Rs 180.03 crore in the quarter ended December 2025 as against Rs 172.71 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales180.03172.71 4 OPM %22.0928.46 - PBDT42.9252.35 -18 PBT37.5446.89 -20 NP22.1334.93 -37 Powered by Capital Market - Live